

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 06727/006001		SERIAL NO. 08/377,518 879,469								
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))				APPLICANT Robert A. Murgita		FILING DATE January 24, 1995								
				GROUP 1812/647										
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL		PATENT NUMBER							ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
SE	AA	4	6	9	2	3	3	2	09/08/87	McMichael	424	88		
SE	AB	4	8	7	7	6	1	0	10/31/89	McMichael	424	88		
SE	AC	4	9	6	6	7	5	3	10/30/90	McMichael	424	88		
SE	AD	4	9	7	0	0	7	1	11/13/90	McMichael	424	88		
SE	AE	5	1	3	0	4	1	5	07/14/92	Tecce et al.	530	324		
SE	AF	5	2	0	6	1	5	3	04/27/93	Tamaoki et al.	435	697		
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION														
		DOCUMENT NUMBER							PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
SE	AG	WO 86/04241							31 Jul 86	PCT				
SE	AH	20058666							09 Jan 90	Japan (Abstract)				x
SE	AI	WO 94/10199							11 May 94	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)														
SE	AJ	Abramsky, et al., Journal of Neuroimmunology, 2:1-7 (1982)												
SE	AK	Abramsky et al., Annals New York Academy of Sciences, pp. 108-115 (1983)												
SE	AL	Aoyagi et al., Gann, 75:809-815 (1984)												
SE	AM	Biddle et al., Breast Cancer Research and Treatment, 10:279-286 (1987) (1987)												
SE	AN	Boismenu et al., Life Sciences, 43:673-681 (1988)												
SE	AO	Brenner et al., Annals New York Academy of Sciences, pp. 208-221 (1981)												
SE	AP	Brenner et al., Proc. Natl. Acad. Sci. USA, 77:3635-3639 (1980)												
EXAMINER Stephen Buckner										DATE CONSIDERED 4/3/96				
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 06727/006001		SERIAL NO. 08/377,916 879,469	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))				APPLICANT Robert A. Murgita		GROUP 1812 1647	
				FILING DATE January 24, 1995			
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
56	BA		Brenner et al., Immunology Letters 167 (1981)				
56	BB		Buamah et al., Clinica Chimica Acta., 139:313-316 (1984)				
56	BC		Buschman et al., Journal of Neuroimmunology 13:315-330 (1987)				
56	BD		Cohen et al., Scand. J. Immunol. 23:211-223 (1986)				
56	BE		Dattwyler et al., Nature, 256:656-657 (1975)				
56	BF		Gershwin et al., The Journal of Immunology, 121:2292-2298 (1978)				
56	BG		Glazier et al., J. Exp. Med., 158:1-8 (1983)				
56	BH		Goidl et al., Developmental of Immunobiology, pp. 35-55 (1979)				
56	BI		Hamel et al., Phenotype and Function of Bone Marrow-Derived T- and Non-T-Cells Activated In Vitro By Alpha-Fetoprotein, In: Biological Activities of Alpha ₁ -Fetoprotein (Vol. I), Mizejewski, G.J. and Jacobson, H.I (eds.), CRC Press, Inc. (Boca Raton, FL), pp. 167-177 (1987)				
56	BJ		Heyward et al., The Lancet, pp. 1161-1162 (1983)				
56	BK		Hooper et al., Human AFP Inhibits Cell Proliferation and NK-Like Cytotoxic Activity Generated in Autologous, But Not In Allogeneic Mixed Lymphocyte Reactions, In: Biological Activities of Alpha ₁ -Fetoprotein, (Vol. II) Mizejewski, G.J. and Jacobson, H.I (eds.), CRC Press, Inc. (Boca Raton, FL), pp. 183-197 (1989)				
56	BL		Hooper et al., Selective Inhibition Of Murine T-Cell Proliferation And Lymphokine-Activated Natural Killer Cell Function By alpha-Fetoprotein, In: Biological Activities of Alpha ₁ -Fetoprotein, (Vol. I) Mizejewski, G.J. and Jacobson, H.I (eds.), CRC Press, Inc. (Boca Raton, FL), pp. 153-165 (1987)				
56	BM		Hooper et al., Cellular Immunology, 63:417-425, (1981)				
EXAMINER Stephen Lucker				DATE CONSIDERED 4/3/96			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
06727/006001SERIAL NO.
08/377,316 879,469INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)APPLICANT
Robert A. MurgitaFILING DATE
January 24, 1995

GROUP 1812 1647

(37 CFR 1.98(b))

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

56	CA	Hooper et al., Oncodevelopmental Biology and Medicine, 3:151-160 (1982)
56	CB	Hoskin et al., Cellular Immunology, 96:163-174 (1985)
56	CC	Hoskin et al., Clin. exp. Immunol., 76:262-267 (1989)
56	CD	Hoskin et al., Analysis Of Pregnancy-Associated Immunoregulatory Pathways, In: Alpha-Fetoprotein and Congenital Disorders, Academic Press, New York, pp. 59-78, (1985)
56	CE	Innis et al., Archives of Biochemistry and Biophysics, 195:128-135 (1979)
56	CF	Ishiguro et al., Cancer, 55:156-159 (1985)
56	CG	Jacobson et al., Cancer Research, 50:415-420 (1990)
56	CH	Jiang et al., Science, 256:1213-1215 (1992)
56	CI	Keller et al., Immunosuppressive Properties of AFP: Role of Estrogens, In: Onco-Developmental Gene Expression, Fishman, W.H. and Sell, S. (eds.), Academic Press, Inc. (New York) pp. 287-295 (1976)
56	CJ	Kikutani et al., Advances in Immunology, 51:285-322 (1992)
56	CK	Line et al., Medical Potential Of AFP As A Tumor Imaging Agent, In: Biological Activities of Alpha ₁ -Fetoprotein (Vol. II), Mizejewski, G.J. and Jacobson, H.I (eds.), CRC Press, Inc. (Boca Raton, FL), pp. 139-148 (1989)
56	CL	Lu et al., The Journal of Immunology, 132:1722-1727 (1984)
56	CM	Masuda et al., Tumor Biol., 15:175-183 (1994)
56	CN	Mizejewski, Gerald J., Laboratory Management, (1987)

EXAMINER

Stephen Gucker

DATE CONSIDERED

4/3/96

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 06727/006001		SERIAL NO. 08/377,316 879,469	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))				APPLICANT Robert A. Murgita		GROUP 18/2/647	
				FILING DATE January 24, 1995			
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
56	DA		Morinaga et al., Proc. Natl. Acad. Sci. USA, 80:4604-4608 (1983)				
56	DB		Moro et al., Tumor Biol., 14:116-130 (1993)				
56	DC		Murgita et al., La Ricerca Clin. Lab., 9:327-342 (1979)				
56	DD		Murgita et al., Prog. Allergy, 29:54-133 (1981)				
56	DE		Murgita et al., The Journal of Experimental Medicine, 141:440-452 (1975)				
56	DF		Murgita et al., The Journal of Experimental Medicine, 141:269-286 (1975)				
56	DG		Murgita et al., Proc. Natl. Acad. Sci. USA, 75:2897-2901 (1978)				
56	DH		Murgita et al., Clin. exp. Immunol., 33:347-256 (1978)				
56	DI		Murgita et al., Scand. J. Immunol., 5:1215-1220 (1976)				
56	DJ		Murgita, Scand. J. Immunol., 5:1003-1014 (1976)				
56	DK		Murgita et al., Nature, 267:257-259 (1977)				
56	DL		Murgita et al., Eur. J. Immunol., 11:957-964 (1981)				
56	DM		Nelson et al., The New England Journal of Medicine, 329:466-471 (1993)				
56	DN		Nishi et al., J. Biochem., 104:968-972 (1988)				
EXAMINER Stephen Zucker				DATE CONSIDERED 4/3/96			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 06727/006001		SERIAL NO. 08/377,310-879,469	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98(b))				APPLICANT Robert A. Murgita		GROUP 7812 1647	
				FILING DATE January 24, 1995			
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
56	EA		O'Neill et al., Oncodevelopmental Biology and Medicine, 3:135-150 (1982)				
56	EB		Peck et al., The Journal of Immunology, 128:1134-1140 (1982)				
56	EC		Peck et al., The Journal of Experimental Medicine, 147:667-683 (1978)				
56	ED		Peck et al., J. Exp. Med., pp. 360-372 (1978)				
56	EE		Sell, S., In: Cancer Markers Diagnostic and Developmental Significance, Sell, S., (ed.), Humana Press, Clifton, NJ pp. 249-293 (1980)				
56	EF		Semeniuk et al., Abstract 2799, Experimental Biology 94 TM , Anaheim, CA (1994)				
56	EG		Soto et al., Proc. Natl. Acad. Sci. USA, 77:2084-2087 (1980)				
56	EH		van Oers et al., Journal of Chromatography, 525:59-69 (1990)				
56	EI		van Oers, et al., J. Exp. Med., 170:811-825 (1989)				
56	EJ		Villacampa et al., Biochemical and Biophysical Research Communications, 122:1322-1327 (1984)				
56	EK		Yamamoto et al., Life Sciences, 46:1679-1686 (1990)				
56	EL		Giuliani et al., Protein Engineering, 2:605-610 (1989)				
EXAMINER			DATE CONSIDERED				
Stephen Gucker			4/3/96				
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Substitute Disclosure Form (PTO-1449)